![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Fusion Antibodies Plc | LSE:FAB | London | Ordinary Share | GB00BDQZGK16 | ORD 4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.40 | 3.30 | 3.50 | 3.40 | 3.40 | 3.40 | 78,622 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.9M | -2.6M | -0.0272 | -1.25 | 3.24M |
Date | Subject | Author | Discuss |
---|---|---|---|
31/1/2024 16:44 | On the way back up again. I wonder if some agreements are on the way? | ![]() cbeadle | |
29/1/2024 15:32 | https://www.londonst | blackhorse23 | |
27/1/2024 09:33 | Sell, sell, sell.Lemmings and mushrooms only. | ![]() ken chung | |
24/1/2024 09:46 | Out now , and going to buy APH ( profit making health care company) | blackhorse23 | |
24/1/2024 09:05 | Disagree entirely keep trying to scare people | ![]() bigjock36 | |
23/1/2024 18:12 | Very touch and go though . Do you really want to be running on fumes and then miss break even could spell disaster. Remember you need a years cash just to keep going as a going concern at results . A fund raise looks almost a certainty here and until clarity in revenues etc become clearer it looks best to wait on the sidelines | ![]() bones698 | |
23/1/2024 17:15 | From Allenby capitals most recent research note in December 23: typically around 50% until about a year ago). As a result of its restructuring, Fusion's total cash cost base has been reduced to c. £250k/month and we anticipate revenue to recover to around these levels by mid FY2025 (i.e. Summer of 2024). The cash position of £500k as of end September should also be expected to be boosted by the receipt of the FY23 R&D tax credit of c. £100k in early 2024. On this basis, we model a cash reach until at least middle of CY 2024, although we note that the company would potentially be trading at close to cashflow breakeven at this point. | ![]() gtc1508 | |
23/1/2024 16:34 | Nobby not another MIN your working on.🤣🤣 | ![]() clocktower | |
23/1/2024 16:30 | I have no particular interest in FAB anymore, it's too small a company. But I would be interested to see any calculations that anyone has done of (a) what FAB's current monthly cash burn is, and (b) therefore what FAB's current cash position is. Do people routinely do these sorts of calculations before investing? JakNife | ![]() jaknife | |
23/1/2024 16:10 | My impression was they hadn’t received the tax credit yet but I could be wrong. He implied this would be an amount to stave off a fundraise for a while and was not generally appreciated by the market. I too am researching it with a view to buying in. I worked in the antibody field and know how difficult it is especially for small companies but there could be value here because of the low market cap. This is the sort of company where it could be useful for to PIs organise together to help them with finance. | ![]() nobbygnome | |
23/1/2024 15:52 | That would be a huge help to get them through Nobbygnome | ![]() cbeadle | |
23/1/2024 15:52 | 263k is the amount of the tax credit in the last accounts. I would have thought the company should have received this by now. | ![]() langland | |
23/1/2024 15:50 | I'm currently researching with a view to buying and would appreciate any feedback you're able/willing to share Nobby as indeed would others I dare say. | ![]() flashheart | |
23/1/2024 15:48 | I should say I am currently researching the company and will be talking with a mutual friend who is an expert in this field. | ![]() nobbygnome | |
23/1/2024 15:44 | I was at the Proactive talk and discovered I worked with Adrian about 20 years ago. We had a good discussion afterwards and wrt finance he said they had a chunky tax credit to come shortly. I don’t know if this has been discussed before but I can’t see it mentioned on a quick read of the last financial results | ![]() nobbygnome | |
23/1/2024 08:09 | That cash position is the great uncertainty, hopefully resolved very shortly so means now is the great opportunity. The NCI collaboration should certainly have put us on the radar well | ![]() cbeadle | |
23/1/2024 07:47 | I think you need to listen to the presentation whereby they are reaching a cash neutral position monthly To me anything in the 4 or 5 is going to allow you to double your money soon | ![]() bigjock36 | |
23/1/2024 06:10 | Don't think I would be topping up yet . Cash position is perilous and suspect another placing coming very soon at a discount say 3p . Might aswell wait until after that is done and get them cheaper if you believe the company will turn things around . Cost cutting etc is good but left it late and turnover needs to increase next results or any faith will be gone . I've seen worse that's for sure but like most they need cash and that's a problem in these markets . | ![]() bones698 | |
22/1/2024 17:39 | Looks like some people did exactly that below 5.5p cbeadle. Time will tell whether they were smart or not. | ![]() cyberbub | |
22/1/2024 14:49 | If I had any spare cash I would top up now | ![]() cbeadle | |
22/1/2024 14:22 | Just another sad troll cyber | ![]() walter walcarpets | |
22/1/2024 13:39 | Blackhorse has been pumping APH across multiple boards for months, here and on LSE, lol. "Good returns", APH has been flat or falling for almost that entire time! LOL. | ![]() cyberbub |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions